Final Program in it's entirety - MyGirlsBlood

Recommendations

Info

Posters, Tuesday and Wednesday Index of Poster Presenters cont’d 17P56 Impact of Acute Bleeding Episodes and Bypassing Agent (BPA) Administration on Patient/Caregiver/Family Daily Activities in Congenital Hemophilia with Inhibitors: Analysis of the Dosing Observational Study in Hemophilia (DOSE) Recht M1 , Neufeld E2 , Sharma V3 , Cooper D4 , Wilke C5 , Gut R4 1Oregon Health and Science University, Portland, OR, U.S.A., 2 3 Childrens Hospital of Boston, MA, U.S.A., Brown Cancer Center, Louisville, KY, U.S.A., 4Novo Nordisk Inc., Princeton, NJ, U.S.A., 5University of Illinois, Chicago, IL, U.S.A. 17P57 Polymorphisms in the VWF Gene and Development of FVIII Inhibitors in Patients with Severe Hemophilia A Repesse Y1 , De Loncamps A1 , Costa C2 , Kaveri S3 , Borel- Derlon A1 , Lacroix-Desmazes S3 1Laboratoire d’hematologie, CHU de Caen, Caen, France, 2AP-HP, Groupe Henri Mondor-Albert Chenevier, Service de Biochimie, UF de Genetique Moleculaire, INSERM Unité 84, Creteil, France., 3Centre de Recherche des Cordeliers, eq 16, Université Pierre et Marie Curie, Paris, France 17P58 The Natural History of Factor VIII Inhibitors in Patients with Congenital Hemophilia A without Immunotolerance Induction Rezende S1 , Caram C2 , de Souza R3 , de Sousa J4 , Cerqueira A5 , van der Bom J6 1Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 2Grupo de Estudo da Hemostasia e Trombose – GETHe/UFMG, 3Prefeitura de Pará de Minas, 4Target M&E Consultoria, and 5Fundação HEMOMINAS, Belo Horizonte, Brazil, 6Leiden University Medical Center, Leiden, the Netherlands 17P59 The Haemophilia RER Network: Characteristics of Patients with Inhibitor in the Registry Rivolta G1 , Tagliaferri A1 , Biasoli C2 , Pedrazzi P3 , Valdrè L4 , Arbasi M5 1Regional Reference Centre For Inherited Bleeding Disorders, University-Hospital of Parma, Parma. Italy, 2Haemophilia Centre of Cesena, Cesena. Italy, 3Haemophilia Centre of Modena, Modena. Italy, 4Haemophilia Centre of Bologna, Bologna. Italy, 5Haemophilia Centre of Piacenza, Piacenza, Italy 17P60 Factor VIII and IX Genotype Characterisation of Hemophilia Patients with Transient or Permanent Inhibitors in Argentina Rossetti L1 , Szurkalo I1 , Primiani L2, 3 , Neme D2, 3 , Candela M1, 2, 3 , Pérez Bianco R1, 2, 3 1Instituto de Investigaciones Hematológicas Mariano R Castex, Academia Nacional de Medicina de Buenos Aires, 2 3 Fundación de la Hemofilia Alfredo Pavlovsky, Grupo Argentino de Estudio de Inhibidores en Hemofilia (GADEI), Buenos Aires, Argentina 72 17P61 Addressing Clinical Issues Related to FVIII Inhibitors Using a Human BCR Transgenic Mouse: The Model Benhida A 1 , VanderElst L 1 , Ectors F 2 , Gilles JG 1 , Jacquemin M 1 , Saint-Remy JM 1 1 Center for Molecular and Vascular Biology, University of Leuven, and 2 GIGA, University of Liège, Belgium 17P62 Addressing Clinical Issues Related to FVIII Inhibitors Using a Human BCR Transgenic Mouse: Formation and Suppression of FVIII Inhibitors Carlier V, Grailly S, Benhida A, Gilles JG, Jacquemin M, Saint- Remy JM Center for Molecular and Vascular Biology, University of Leuven, Belgium 17P63 European Initiative to Prevent Joint Damage in Hemophilia Children with Inhibitors (ENJOIH) – A Prospective Study Santagostino E1 , Auerswald G2 , Jimenez-Yuste V3 , Ljung R4 , Morfini M5 , Rocino A6 , Young G7 1A. Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Foundation, PoliclinicoMaggiore Hospital, Milan, Italy, 2Prof. Hess Children’s Hospital, Klinikum Bremen- Mitte, Bremen, Germany, 3Haematology Department, Hospital Universitario La Paz, Madrid, Spain, 4Department of Paediatrics and Coagulation Disorders, University Hospital, Malmö, Sweden, 5Agency for Hemophilia, Reference Center for Inherited Bleeding Disorders of Tuscany, Department of Emergency and Reception, Azienda Ospedaliero Universitaria Careggi, Florence, Italy, 6Haemophilia and Thrombosis Center, S.Giovanni Bosco Hospital, Naples, Italy, 7Children’s Hospital of Orange County, Orange, CA, U.S.A. 17P64 The Distinct Role of the Hemostatic Components in the Mode of Action of FEIBA ® Varadi K, Schoppmann A, Turecek P, Gritsch H, Ehrlich H, Schwarz H Baxter BioScience, Vienna, Austria 17P65 [18-F] Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Imaging for Detection of Hemophilic Arthropathy in a Rabbit Model Shammas A1 , Charron M1 , Metser U2 , Amirabadi A1 , Zhong A1 , Doria A1 1 2 The Hospital For Sick Children, and Princess Margaret Hospital, Toronto, Canada
Index of Poster Presenters cont’d 17P66 Frequency of Factor VIII (FVIII) Inhibitor Levels in Patients with Hemophilia A in Karachi Shamsi T1 , Borhany M1 , Ansari S1 , Kumari M1 , Sangji Z3 , Ur Rehman Z2 1National Institute of Blood Disease and Bone Marrow Transplantation, 2Fatimid Foundation, and 3Husaini Blood Bank, Karachi, Pakistan 17P67 Prospective ADVATE Immune Tolerance Induction Registry (PAIR): An Update Spotts G, Luu H, Wu L, Stephens D, McCulloch-Bayr A, Ewenstein B Baxter Healthcare Corporation, Westlake Village, CA, U.S.A. 17P68 Sequential Therapy with APCC and rFVIIA in Two Hemophilia Inhibitor Patients Undergoing Four Dental Extraction Procedures Stefanska-Windyga E, Czubak G, Baran B, Windyga J Department of Disorders of Haemostasis and Internal Medicine, Institute Of Haematology and Transfusion Medicine, Warsaw, Poland 17P69 The Natural History of Inhibitors on 545 HA and 92 HB Patients Followed Up at Castelfranco Veneto Hemophilia Centre Tagariello G, Sartori R, Tassinari C, Belvini D, Salviato R, Radossi PHaemophilia Center Transfusion and Haematology Haemophilia, Castelfranco Veneto, Italy 17P70 Efficacy of Rituximab as Monotherapy in the Treatment of Children with Hemophilia and High Response Inhibitors Tlacuilo-Parra A, García-Mendoza A, Garibaldi-Covarrubias R, Soto-Padilla J, Toro-Castro L, García-Delgadillo M UMAE Hospital De Pediatria CMNO IMSS, Guadalajara, Mexico 17P71 Recombinant Glycopegylated FIX (40K PEG-Rfix) Demonstrates Prolonged Half-Life in Several Animal Species Hansen L1 , Ezban M1 , Henrik O1 , Nichols TC2 , Agersø H1 , Tranholm M1 1 2 Novo Nordisk A/S, Maaloev, Denmark, University of North Carolina, Chapel Hill, NC, U.S.A. 17P72 Patient/Caregiver-Reported Bleed Symptoms and Reasons for Starting/Stopping Treatment with Recombinant Factor VIIa (rFVIIa): Analysis of the Dosing Observational Study in Hemophilia (DOSE) Valentino L 1 , Walsh C 2 , Reding M 3 , Young G 4 , Tugal O 5 , Cooper D 6 1 RUSH University Medical Center, Chicago, IL, U.S.A., 2 Mount Sinai Medical Center, New York, NY, U.S.A., 3 University of Minnesota, Fairview, MN, U.S.A. 4 Childrens Hospital of Los Angeles, CA, U.S.A. 5 New York Medical College, Westchester County, NY, U.S.A., 6 Novo Nordisk Inc., Princeton, NJ, U.S.A. 17P73 Incidence of Inhibitors among Multi-Transfused Patients with Hemophilia A: A Meta-Analysis of Prospective Cohort Studies Van Der Bom J1 , Kamphuisen P2 , Navickis R3 , Wilkes M3 1Leiden University Medical Center, Leiden, the Netherlands, 2Amsterdam Medical Center, Amsterdam, the Netherlands, 3Hygeia Associates, San Francisco, CA, U.S.A. 17P74 Comparison of ITT-Course and Outcome in Hemophilia Inhibitor Patients Treated with APCC and/or rFVIIa Vidovic N, Petri M, Goldmann G, Niemann B, Horneff S, Brackmann HH, Oldenburg J Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Germany 17P75 The Prevalence of Factor VIII Inhibitors and Genetic Aspects of Inhibitor Development in Chinese Patients with Hemophilia A Wang X1 , Yang R2 , Zhao Y3 , Wu J4 , Sun J5 , Zhang X6 1 2 3 Shanghai Ruijin Hospital, Peking Union Hospital, China Institute of Hematology and Blood Disease Hospital, 4Anhui 5 Provincial Hospital, Guangzhou Nanfang Hospital, 6Shandong Blood Center, Republic of China 17P76 Serial Courses of Rituximab as Effective Treatment of Inhibitors to FVIII or FIX in Adult Patients with Severe Hemophilia A (HA) or B (HB) Wieduwilt M, Phelan D, Karp S, Francis D, Fogarty P Comprehensive Hemophilia Treatment Center, Adult Program, University of California, San Francisco, CA, U.S.A. 17P77 Switch to Recombinant Factor VIII after Previously Successful Immune Tolerance Induction with FVIII/von Willebrand Factor Concentrates in Children with Severe Hemophilia A Pergantou H, Xafaki P, Platokouki H Haemophilia/Haemostasis Unit, Aghia Sophia Children’s Hospital, Athens, Greece 73 Posters, Tuesday and Wednesday
Page 1 and 2:
Hemophilia Saturday, July 10 - Wedn
Page 3 and 4:
Pre-Congress Sessions cont’d 10:3
Page 5 and 6:
Pre-Congress Sessions cont’d 15:0
Page 7 and 8: Congress Sessions cont’d S1.6 - M
Page 9 and 10: Congress Sessions cont’d S2.5 - M
Page 11 and 12: Congress Sessions cont’d n Long T
Page 13 and 14: Congress Sessions cont’d M2.4 - M
Page 15 and 16: Congress Sessions cont’d Tuesday,
Page 17 and 18: Congress Sessions cont’d 14:15 -
Page 19 and 20: Congress Sessions cont’d T3.4 - M
Page 21 and 22: Congress Sessions cont’d n Inhibi
Page 23 and 24: Congress Sessions cont’d W2.4 - L
Page 25 and 26: Index of Speakers cont’d Halimeh,
Page 27 and 28: Index of Poster Presenters Sunday a
Page 29 and 30: Index of Poster Presenters cont’d
Page 57: Index of Poster Presenters cont’d
show all

Final Program in it's entirety - MyGirlsBlood

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?